Health experts already knew that curbing blood pressure can help avoid strokes, heart attacks, and other serious health problems.
Now, French doctors report that lowering blood pressure may halt or slow the progression of brain abnormalities called white matter hyperintensities (WMH). Their study appears in Circulation.
WMH and High Blood Pressure
"People with high blood pressure are more likely to develop WMH, and a larger volume of WMH are associated with cognitive decline, an increased risk of dementia, and accelerated brain aging in some hypertensive patients," says Christophe Tzourio, MD, PhD, in an American Heart Association news release.
Tzourio works in Paris at INSERM, France's national institute for health and medical research. With colleagues, he studied WMH and blood pressure treatment.
Brain and Blood Pressure Study
At the study's start, about half of the group had high blood pressure. MRI brain scans showed that 42% had no WMH, 13% had moderate WMH, and 19% had severe WMH.
About a third of the group got medicine to treat their high blood pressure. They either got an ACE inhibitor and a diuretic (water pills) or just the ACE inhibitor. The rest of the patients got a fake drug (placebo).
About three years later, more brain scans were done. The results:
- 24 people had developed new WMH.
- People taking blood pressure medicines were 43% less likely to have new WMH than those taking the placebo.
- New WMH were smaller in patients taking the blood pressure medicines.
As expected, blood pressure dropped more with the prescription medicines than with the placebos.
Check Your Blood Pressure
The researchers call for more studies to find the best blood pressure treatments to curb WMH.
Meanwhile, there are plenty of reasons to get high blood pressure under control. "Uncontrolled high blood pressure can lead to stroke, heart attack, heart failure, or kidney failure," states the web site of the American Heart Association (AHA).
Nearly one in three U.S. adults has high blood pressure, but almost a third of them don't know it, according to the AHA.
The study was sponsored in part by Servier, a French pharmaceutical company.